Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

Kaum andere medizinische Fachrichtungen haben sie derart entwickelt wie die Neurologie – besondere Fortschritte in der Behandlung der Multiplen Sklerose (MS) sind zu festzuhalten. Krankheitsmodifizierende Therapien (DMT) ermöglichen eine hocheffektive Beeinflussung des Krankheitsverlaufs. Dieser Beitrag versucht einen Überblick zu geben, welche Immuntherapeutika zur individualisierten Behandlung von MS-Patienten zur Verfügung stehen und praktische Hinweise für deren Anwendung.

Kernaussagen

• Heutzutage sind zahlreiche Immuntherapien für die Behandlung der MS zugelassen.

• Die Therapieentscheidung soll individuell getroffen werden.

• Ein Induktion- und ein Eskalationsschema werden aktuell breit diskutiert, diese können auch abhängig von den Charakteristika der Patienten geprüft werden.

• Die MS-Behandlung kann sich mehreren Faktoren inkl. berufliches Leben und Familienplanung anpassen.

• Ein regelmäßiges Monitoring und Überwachung von Wirksamkeit, aber auch von Nebenwirkungen und Komplikationen der Therapie ist nötig.

• Weitere Medikamente mit neuen Wirkstoffen sind in Erforschung und werden in den kommenden Jahren verfügbar sein.

Publication History

Article published online:
01 June 2023

• Literatur

• 1 Li R, Tang H, Burns JC. et al. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol 2022; 143: 505-521
• 2 Tintoré M. Early MS treatment. Int MS J 2007; 14: 5-10
• 3 AlSharoqi IA, Aljumah M, Bohlega S. et al. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. Neurol Ther 2020; 9: 55-66
• 4 Brown JWL, Coles A, Horakova D. et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 2019; 321: 175-187
• 5 Wattjes MP, Ciccarelli O, Reich DS. et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021; 20: 653-670
• 6 Wiendl H, Gold R, Berger T. et al. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper). Nervenarzt 2021; 92: 773-801
• 7 Hojati Z, Kay M, Dehghanian F. Chapter 15 – Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis. In: Minagar A. Multiple Sclerosis. San Diego: Academic Press; 2016: 365-392
• 8 Kappos L. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497
• 9 La Mantia L, Vacchi L, Di Pietrantonj C. et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012; 1: CD005181
• 10 Hellwig K, Geissbuehler Y, Sabidó M. et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol 2020; 267: 1715-1723
• 11 Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007; 6: 469-475
• 12 Khan O, Rieckmann P, Boyko A. et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73: 705-713
• 13 Boster A, Bartoszek MP, O'Connell C. et al. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011; 4: 319-332
• 14 Wolinsky JS, Narayana PA, O`Connor P. et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24
• 15 Comi G, Martinelli V, Rodegher M. et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511
• 16 Gold R, Kappos L, Arnold DL. et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med 2012; 367: 1098-1107
• 17 Wray S, Then Bergh F, Wundes A. et al. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. Adv Ther 2022; 39: 1810-1831
• 18 Fox RJ, Miller DH, Phillips JT. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097
• 19 Naismith RT, Wundes A, Ziemssen T. et al. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs 2020; 34: 185-196
• 20 O'Connor P, Wolinsky JS, Confavreux C. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303
• 21 Confavreux C, O´Connor P, Comi G. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 247-256
• 22 Vermersch P, Czlonkowska A, Grimaldi LME. et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014; 20: 705-716
• 23 Göttle P, Manousi A, Kremer D. et al. Teriflunomide promotes oligodendroglial differentiation and myelination. J Neuroinflammation 2018; 15: 76
• 24 Malla B, Cotten S, Ulshoefer R. et al. Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. Ther Adv Chronic Dis 2020; 11
• 25 Constantinescu V, Haase R, Akgün K. et al. S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review. Ther Adv Neurol Disord 2022; 15
• 26 Calabresi PA, Radue EW, Goodin D. et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556
• 27 Kappos L, Fox RJ, Burcklen M. et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021; 78: 558-567
• 28 Cohen JA, Comi G, Selmaj KW. et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 2019; 18: 1021-1033
• 29 Kappos L, Bar-Or A, Cree BAC. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391: 1263-1273
• 30 Roach CA, Cross AH. Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. Front Neurol 2020; 11: 595547
• 31 Hauser SL, Waubant E, Arnold DL. et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. N Engl J Med 2008; 358: 676-688
• 32 Hauser SL, Bar-Or A, Comi G. et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2016; 376: 221-234
• 33 Montalban X, Hauser SL, Kappos L. et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2016; 376: 209-220
• 34 Fox EJ, Markowitz C, Applebee A. et al. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler 2018; 24: 1862-1870
• 35 Comi G, Bermel R, Bar-Or A. et al. A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis. Neurology 2022; 98 (Suppl. 18) 652
• 36 Hauser SL, Bar-Or A, Cohen JA. et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020; 383: 546-557
• 37 Kümpfel T, Thiel S, Meinl I. et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. Neurol Neuroimmunol Neuroinflamm 2021; 8: e913
• 38 Schwake C, Steinle J, Thiel S. et al. Effects of anti-CD20 therapies on infant health and physiological B-cell development if administered before or during pregnancy and/or lactation. ECTRIMS 2022, Abstract O036. Mult Scler J 2022; 28 (Suppl. 03) 3-129
• 39 Selewski DT, Shah GV, Segal BM. et al. Natalizumab (Tysabri). AJNR Am J Neuroradiol 2010; 31: 1588-1590
• 40 Polman CH, O'Connor PW, Havrdova E. et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med 2006; 354: 899-910
• 41 Butzkueven H, Kappos L, Wiendl H. et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020; 91: 660-668
• 42 Foley JF, Defer G, Ryerson LZ. et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022; 21: 608-619
• 43 Trojano M, Ramió-Torrentà L, Grimaldi LM. et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021; 27: 2240-2253
• 44 Ho PR, Koendgen H, Campbell N. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925-933
• 45 Friend S, Richman S, Bloomgren G. et al. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 2016; 16: 150
• 46 Cohen JA, Coles AJ, Arnold DL. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828
• 47 Havrdova E, Arnold DL, Cohen JA. et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89: 1107-1116
• 48 Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017; 10: 343-359
• 49 Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8: 31-45
• 50 Saxena G, Moore JM, Jones M. et al. Detecting and predicting neutralization of alemtuzumab responses in MS. Neurol Neuroimmunol Neuroinflamm 2020; 7: e767
• 51 Giovannoni G, Comi G, Cook S. et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med 2010; 362: 416-426
• 52 Rice GPA, Filippi M, Comi G. Cladribine and progressive MS. Clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145-1155
• 53 Geladaris A, Torke S, Weber MS. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?. CNS Drugs 2022; 36: 1019-1030
• 54 Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183-193